GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Enanta Pharmaceuticals
Enanta is a biotech company historically focused on treating hepatitis C. Its stock price reflects its efforts to diversify and develop new drugs to treat other viral diseases following the success of its first blockbuster.
Share prices of companies in the market segment - Pharma virus
Enanta Pharmaceuticals is a biotechnology company focused on the discovery and development of small-molecule drugs for the treatment of viral infections, primarily hepatitis C and COVID-19. We classify it in the Pharmaceuticals (Virology) segment, which is at the forefront of the fight against pandemics. The chart below shows the dynamics of this sector.
Broad Market Index - GURU.Markets
Enanta Pharmaceuticals is a biopharmaceutical company developing treatments for viral infections such as hepatitis C and respiratory syncytial virus (RSV). As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ENTA - Daily change in the company's share price Enanta Pharmaceuticals
Change_co for Enanta, a biopharmaceutical company, measures its volatility. It reflects sensitivity to the results of clinical trials of its antiviral drugs. This metric is a key component of formulas on System.GURU.Markets for biotech sector analysis.
Daily change in the price of a set of shares in a market segment - Pharma virus
Enanta Pharmaceuticals, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ENTA, which focuses on viral disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Enanta Pharmaceuticals is a biotech company specializing in the development of antiviral drugs. Its research successes and failures cause sharp fluctuations in its stock price. This scientifically driven volatility is an important part of the overall stock market's varied performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Enanta Pharmaceuticals
For Enanta Pharmaceuticals, year-over-year performance is a story of its transition from hepatitis C to new challenges. Its market cap change over the past 12 months reflects progress in clinical trials of its drugs for respiratory viruses (RSV) and COVID-19. Success in these areas is fundamental to its future growth after the end of its royalties from AbbVie.
Annual dynamics of market capitalization of the market segment - Pharma virus
Enanta Pharmaceuticals, Inc. is a biotech company specializing in the development of antiviral drugs. Its success is based on royalties from its hepatitis C treatment technology and its own R&D. The chart below shows how its hybrid model and clinical trial results influence its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Enanta is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Enanta Pharmaceuticals
Enanta Pharmaceuticals (Pharmavirus) develops antiviral drugs. Its Perf_Month_Co is extremely sensitive to clinical trial cycles. Monthly increases and decreases reflect the results of key research phases, as well as patent protection and partnership news.
Monthly dynamics of market capitalization of the market segment - Pharma virus
This chart reflects the dynamics of the biotech sector, particularly the antiviral drug segment. For Enanta, which specializes in this area, it serves as a backdrop. Its movements demonstrate how clinical trial successes and competition influence investor sentiment across the industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Enanta Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for viral infections such as hepatitis C and COVID-19. Its value is determined by the results of clinical trials. The overall market chart provides only background information, while Enanta's performance is driven by scientific news and regulatory decisions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biotech company focused on treating viral diseases such as hepatitis C and respiratory syncytial virus (RSV). Its weekly stock price is driven by news of clinical trials and royalties from its partner, AbbVie.
Weekly dynamics of market capitalization of the market segment - Pharma virus
Enanta Pharmaceuticals specializes in developing antiviral drugs, particularly for the treatment of hepatitis C and respiratory viruses. The company's success depends on the effectiveness of its drugs and the competitive environment. The chart below shows how development news and the epidemiological situation affect its stock price.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Enanta is a pharmaceutical company whose stock moves on news about clinical trials of antiviral drugs. The chart clearly demonstrates how much its performance is driven by scientific news and the epidemiological situation, rather than the market.
Market capitalization of the company, segment and market as a whole
ENTA - Market capitalization of the company Enanta Pharmaceuticals
Enanta Pharmaceuticals' market capitalization dynamics reflect its focus on antiviral drug development. Its chart shows both the successes associated with its licensing fees for hepatitis C drugs and the volatility associated with the trial results of its own drugs for other viral infections.
ENTA - Share of the company's market capitalization Enanta Pharmaceuticals within the market segment - Pharma virus
Enanta Pharmaceuticals is a biotech company specializing in developing treatments for viral infections, primarily hepatitis C and COVID-19. Its market share reflects the success of its partnerships with major pharmaceutical companies. The chart shows how its research translates into royalties and new developments.
Market capitalization of the market segment - Pharma virus
The chart below shows the overall value of the biotech sector. Enanta Pharmaceuticals is a company specializing in the development of antiviral drugs, known for its contributions to the development of hepatitis C treatments. Its market history exemplifies how a successful partnership with a giant (AbbVie) can yield tremendous success.
Market capitalization of all companies included in a broad market index - GURU.Markets
Enanta Pharmaceuticals is a biotech company specializing in the development of antiviral drugs, particularly for the treatment of hepatitis C and respiratory viruses. Its market capitalization reflects its scientific success. The chart below shows the economic weight of companies fighting viral diseases.
Book value capitalization of the company, segment and market as a whole
ENTA - Book value capitalization of the company Enanta Pharmaceuticals
Enanta's foundation is its R&D platform, focused on developing antiviral drugs for diseases such as hepatitis B and respiratory viruses, as well as royalties from its hepatitis C developments. The chart is a story of a biotech company using revenue from past successes to fund its future drug pipeline.
ENTA - Share of the company's book capitalization Enanta Pharmaceuticals within the market segment - Pharma virus
Enanta Pharmaceuticals focuses on developing antiviral drugs. The chart shows its share of actual R&D assets. These include its chemical and biological laboratories, where they create small molecules to combat viruses such as hepatitis C and COVID-19.
Market segment balance sheet capitalization - Pharma virus
Enanta, which develops antiviral drugs, has a lightweight, R&D-focused model. The chart below shows the capital intensity of the pharmaceutical sector, highlighting its research-intensive business model.
Book value of all companies included in the broad market index - GURU.Markets
Enanta Pharmaceuticals is a biotechnology company focused on treating viral diseases such as hepatitis C and COVID-19. Its assets include its scientific platform. Its stake in BCap_All provides the foundation for R&D, which contributes to the global fight against infectious diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biopharmaceutical company. Its assets are valued based on its scientific platform for developing antiviral drugs and royalties from its successful hepatitis C treatment.
Market to book capitalization ratio in a market segment - Pharma virus
Enanta Pharmaceuticals is a biotech company specializing in antiviral drugs. Its value is determined by its pipeline and royalties from existing licenses. This metric represents a premium to book value, reflecting its scientific potential.
Market to book capitalization ratio for the market as a whole
Enanta Pharmaceuticals is a biotech company specializing in the treatment of viral diseases such as hepatitis C and COVID-19. Its valuation depends on the success of its existing and future drugs. This chart demonstrates the premium the market is willing to pay for scientific breakthroughs in the fight against global health threats.
Debts of the company, segment and market as a whole
ENTA - Company debts Enanta Pharmaceuticals
Enanta Pharmaceuticals, a biotech focused on antiviral drugs, is using its strong balance sheet and royalty cash flow to fund new research. The company maintains a conservative debt policy, and its capital is being used to develop treatments for diseases such as respiratory syncytial virus (RSV) and hepatitis B.
Market segment debts - Pharma virus
Enanta Pharmaceuticals is a biotech company specializing in developing drugs to treat viral infections such as hepatitis C and COVID-19. Developing antiviral drugs is a lengthy and expensive process. This chart shows how the company funds its clinical programs, often in partnership with major pharmaceutical companies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Enanta Pharmaceuticals
Enanta Pharmaceuticals specializes in developing antiviral drugs. This process requires significant and long-term investments in R&D. This chart shows the company's reliance on debt to finance its clinical trials. This is a key indicator of its financial stability as it prepares to bring the drug to market.
Market segment debt to market segment book capitalization - Pharma virus
Enanta Pharmaceuticals is a biotech company focused on developing treatments for viral diseases such as hepatitis C and COVID-19. This chart shows debt trends in the sector. It helps assess how the company, which receives royalties from successful products, manages its capital and funds the development of new drugs.
Debt to book value of all companies in the market
Enanta Pharmaceuticals is a biopharmaceutical company focused on treating viral diseases such as hepatitis C and COVID-19. Companies with approved products generate revenue but may use debt to fund new research. This chart helps assess whether Enanta is being conservative in funding R&D from profits or whether it is raising debt to accelerate the development of new drugs.
P/E of the company, segment and market as a whole
P/E - Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for viral diseases such as hepatitis C and COVID-19. This chart shows how the market values its scientific pipeline and royalty revenue. This valuation depends on the success of its drugs and its ability to create new drugs.
P/E of the market segment - Pharma virus
This chart for biopharmaceutical companies serves as a benchmark for Enanta. It reflects how investors value the sector on average. Comparisons with this chart help understand how the market views Enanta's expertise in antiviral drugs (especially its legacy in treating hepatitis C) and its current developments compared to other biotechs.
P/E of the market as a whole
Enanta Pharmaceuticals specializes in developing drugs to treat viral infections, such as hepatitis C and respiratory viruses. Its success depends on clinical trials and competition. This chart of overall biotech risk appetite shows whether investors are willing to fund lengthy and expensive research in this important but unpredictable field.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biotechnology company focused on developing drugs to treat viral infections and liver diseases. This graph reflects expectations for its research platform. Its valuation depends on the success of its clinical trials and royalties from partner programs, such as those in the hepatitis C field.
%20P%2FE%20Enanta%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Enanta-Pharmaceuticals&v=1772513736601 "Chart of the company's future (projected) P/E Enanta Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma virus
Enanta Pharmaceuticals is a biotechnology company focused on the discovery and development of small-molecule drugs for the treatment of viral infections. This chart reflects investor expectations for the company's profitability relative to the sector. It provides insight into how the market views its research programs following its success in treating hepatitis C.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772513736615 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
Enanta Pharmaceuticals is a biotechnology company focused on developing small-molecule drugs for the treatment of viral infections and liver diseases. Against the backdrop of general market expectations, as illustrated by this chart, Enanta's business is driven by scientific advances. Their royalties from hepatitis C drugs and progress in drug development are their primary drivers.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513736639 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biotechnology company specializing in the development of small-molecule drugs for the treatment of viral infections, best known for its contributions to the development of hepatitis C treatments. This chart shows the financial results of the company, which is focused on fighting viral diseases.
Profit of companies in the market segment - Pharma virus
Enanta Pharmaceuticals specializes in developing small-molecule drugs for the treatment of viral infections, such as hepatitis C and respiratory viruses. This chart shows profitability in the pharmaceutical sector. For ENTA, this reflects their success in developing blockbuster drugs in partnership with major pharmaceutical companies, which provides them with stable royalties.
Overall market profit
Enanta Pharmaceuticals is a biotechnology company focused on developing small-molecule drugs for the treatment of viral infections, such as hepatitis C and respiratory syncytial virus (RSV). The company has a successful track record of commercialization. Its growth is driven by its pipeline. This chart does not reflect the specifics of the antiviral drug market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biotech company focused on treating viral diseases, best known for its contributions to hepatitis C treatments. The earnings forecast presented here depends on royalties from existing drugs and, more importantly, on the success of its new developments, such as those against respiratory syncytial virus (RSV).
%20profit%20of%20the%20company%20Enanta%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Enanta-Pharmaceuticals&v=1772513736733 "Graph of future (projected) profit of the company Enanta Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma virus
Enanta Pharmaceuticals specializes in developing antiviral drugs, particularly for the treatment of hepatitis C and respiratory viruses. The profit forecast for this sector depends on the success of clinical trials and the epidemiological situation. This chart reflects analyst expectations for the future of the antiviral market, which is always in need of innovation.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772513736748 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
Enanta Pharmaceuticals specializes in developing drugs to treat viral infections such as hepatitis C and COVID-19. The company's success depends on the results of clinical trials. The market revenue forecasts shown here impact overall pharmaceutical industry funding and pandemic preparedness.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513736772 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biotech company specializing in developing treatments for viral diseases, specifically hepatitis C and COVID-19. This chart shows how the market values its revenue, which consists of royalties from partners. This value is highly dependent on the success of its drugs and progress in clinical trials.
P/S market segment - Pharma virus
Enanta Pharmaceuticals is a biotechnology company specializing in the development of small-molecule drugs for the treatment of viral infections, primarily hepatitis C and respiratory viruses. This chart reflects the average revenue estimate for the sector, providing insight into how the market values Enanta's scientific expertise and clinical pipeline.
P/S of the market as a whole
Enanta Pharmaceuticals is a biotech company specializing in the development of drugs to treat viral infections, particularly hepatitis C and respiratory syncytial virus (RSV). Its revenue depends on royalties and the success of new developments. This chart provides a general market context for assessing investor sentiment toward innovative healthcare companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biotechnology company specializing in the development of small-molecule drugs for the treatment of viral infections, primarily hepatitis C and respiratory viruses. This chart shows how investors estimate the company's future revenue from royalties and potential new drugs.
%20P%2FS%20Enanta%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Enanta-Pharmaceuticals&v=1772513736853 "The graph of the company's future (projected) P/S Enanta Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma virus
Enanta Pharmaceuticals is a biotechnology company specializing in the development of small-molecule drugs for the treatment of viral infections and liver diseases. Its greatest success is its involvement in the development of hepatitis C drugs. This chart reflects the market's assessment of its scientific platform and its ability to develop new drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772513736874 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
Enanta Pharmaceuticals is a biotech company specializing in developing treatments for viral infections such as hepatitis C and COVID-19. Their success depends on partnerships and trial results. This market optimism curve is important. It influences the willingness of large pharmaceutical companies to invest in their developments and the overall funding volume in the sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513736905 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biotech company that has successfully developed a treatment for hepatitis C (in partnership with AbbVie) and has a pipeline of antiviral drugs. This chart reflects royalty revenue for a commercialized product. Future revenue growth will depend on the success of its clinical programs.
Sales of companies in the market segment - Pharma virus
Enanta Pharmaceuticals is a biotech company specializing in the development of small-molecule drugs for the treatment of viral infections and liver diseases. Their greatest success is their involvement in the development of a blockbuster treatment for hepatitis C. Their revenue structure primarily consists of royalties from sales of these drugs by their partners.
Overall market sales
Enanta Pharmaceuticals is a biopharmaceutical company specializing in the development of small-molecule drugs for the treatment of viral infections and liver diseases. The company is known for its contributions to the development of hepatitis C therapy. This total revenue chart includes the healthcare sector, where ENTA continues to combat serious viral threats.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biopharmaceutical company specializing in the development of antiviral drugs, particularly for the treatment of hepatitis C and respiratory syncytial virus (RSV). This graph reflects expectations for the success of its clinical programs and the demand for new antiviral agents.
%20sales%20of%20the%20company%20Enanta%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Enanta-Pharmaceuticals&v=1772513736938 "Schedule of future (projected) sales of the company Enanta Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma virus
Enanta Pharmaceuticals is a biotechnology company specializing in the development of small-molecule drugs for the treatment of viral infections and liver diseases. This chart shows forecasts for the antiviral drug market. It reflects the need for new treatments for diseases such as hepatitis C, respiratory viruses, and COVID-19.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772513736952 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
Enanta Pharmaceuticals, a biotech company focused on treating viral diseases, sees this chart as a reflection of global health priorities. The robust economic growth projected here provides funding for the fight against diseases such as hepatitis C and respiratory syncytial virus (RSV), for which Enanta is developing drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513736965 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biotech company focused on developing drugs to treat viral diseases, particularly hepatitis C and respiratory viruses. Its financial model includes royalties from successful products and expenditures on new research. This chart shows the balance between current revenue and investments in future drugs.
Market segment marginality - Pharma virus
Enanta Pharmaceuticals specializes in developing drugs to treat viral infections, primarily hepatitis C, and respiratory diseases. This indicator reflects the commercial success of its developments and royalties. This high result demonstrates the significant contribution of the company to the creation of effective antiviral therapies.
Market marginality as a whole
Enanta Pharmaceuticals is a biotechnology company specializing in the development of antiviral drugs. Its success depends on clinical trial results and competition in this field. This overall profitability chart is not related to scientific progress, which is the only significant factor for Enanta.
Employees in the company, segment and market as a whole
Number of employees in the company Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biopharmaceutical company that uses its chemistry expertise to develop small molecules for the treatment of viral infections and liver diseases. This chart shows the team of scientists who played a key role in the development of drugs for the treatment of hepatitis C and are now working on new drugs for respiratory viruses.
Share of the company's employees Enanta Pharmaceuticals within the market segment - Pharma virus
Enanta Pharmaceuticals is a biotechnology company focused on developing small molecules to treat viral infections such as hepatitis C and COVID-19. Its scientific development requires a team of highly skilled organic chemists and virologists. This graph reflects its research intensity and the concentration of talent needed to combat global viral threats.
Number of employees in the market segment - Pharma virus
Enanta Pharmaceuticals is a biotechnology company specializing in the development of antiviral drugs, particularly for the treatment of hepatitis C and respiratory viruses. This graphic shows a team of virologists and chemists at the forefront of the fight against infectious diseases, creating new medicines to protect public health.
Number of employees in the market as a whole
Enanta Pharmaceuticals is a biotechnology company focused on developing treatments for viral diseases such as hepatitis C and respiratory viruses. The overall economic situation, reflected in the employment chart, is important for ensuring access to their medications. Stable employment supports healthcare and insurance systems, making innovative treatments accessible.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals is a biopharmaceutical company focused on treating viral diseases. This chart illustrates their model for successful biotech. Their high market capitalization per employee reflects their existing pipeline of commercialized drugs (for example, for hepatitis C), the royalties from which generate huge cash flow despite their small staff.
%20of%20the%20company%20Enanta%20Pharmaceuticals%20(ENTA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Enanta-Pharmaceuticals-ENTA&v=1772513737016 "Chart of market capitalization per employee (in thousands of dollars) of the company Enanta Pharmaceuticals (ENTA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
Enanta Pharmaceuticals is a biotech company focused on developing treatments for viral infections, including hepatitis C and COVID-19. Its value is determined by the success of its research programs. This chart shows how investors evaluate its research potential per employee compared to other biotech companies.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772513737033 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
Enanta Pharmaceuticals is a biopharmaceutical company specializing in developing drugs for viral diseases such as hepatitis C and respiratory syncytial virus (RSV). This metric reflects the value of its scientific platform and shows how the market views its ability to develop new antiviral drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513737057 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Enanta Pharmaceuticals (ENTA)
Enanta is a biotech company known for its discovery of hepatitis C drugs (licensed to AbbVie). This chart illustrates their successful R&D model. They receive royalties from past successes, ensuring high profits for their current staff, who are now focused on developing new antiviral drugs.
%20Chart%20Enanta%20Pharmaceuticals%20(ENTA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Enanta-Pharmaceuticals-ENTA&v=1772513737061 "Company Profit Per Employee (in thousands of dollars) Chart Enanta Pharmaceuticals (ENTA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
Enanta Pharmaceuticals is a biotech company specializing in the development of small-molecule drugs for the treatment of viral infections, primarily hepatitis C (where they have already achieved success) and respiratory viruses (RSV). This chart represents an industry benchmark. It reflects how effectively the R&D team creates new drugs capable of generating significant revenue or royalties.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772513737075 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
Enanta Pharmaceuticals is a biotech company specializing in antiviral drugs. Their greatest success is their involvement in the development of hepatitis C drugs (in partnership with AbbVie), which generates royalties. This chart shows the balance between passive royalty income and R&D costs (negative profit) per scientist in the search for new antiviral hits.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513737078 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals is a biotech company focused on developing drugs against viral diseases. This chart shows a royalty-based model. A significant portion of the company's revenue per employee is generated from royalties paid to AbbVie for the technology used in their blockbuster hepatitis C treatment.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Enanta-Pharmaceuticals-ENTA&v=1772513737080 "Sales chart per company employee Enanta Pharmaceuticals (ENTA)")
Sales per employee in the market segment - Pharma virus
Enanta Pharmaceuticals (ENTA) is a biotech focused on viral diseases. Their main success is developing (with AbbVie) drugs for hepatitis C. Their revenue comes primarily from royalties. This chart shows how effective their R&D model (scientists) is in generating this passive income per employee.
Sales per employee for the market as a whole
Enanta is a biotech company focused on fighting viral diseases. Their main success is royalties from AbbVie for their Hepatitis C treatment. They are currently developing drugs for RSV. This chart shows the high revenue (royalties) generated by their R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company Enanta Pharmaceuticals (ENTA)
Enanta (ENTA) is a biotech company specializing in the development of small-molecule drugs for viral infections, best known for its contributions to hepatitis C therapy. This chart shows short bets. The rise in shorts may reflect concerns about their reliance on royalties or failures in new drug development (for example, for RSV or COVID-19).
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Enanta-Pharmaceuticals-ENTA&v=1772513737103 "Short Shares Chart for the Company Enanta Pharmaceuticals (ENTA)")
Shares shorted by market segment - Pharma virus
Enanta (ENTA) is a biotech company specializing in the development of small-molecule drugs for the treatment of viral infections, known for its contributions to hepatitis C therapy. This chart demonstrates the general skepticism in the biotech sector. It summarizes the bearish bets, reflecting concerns about the risks of clinical trials.
Shares shorted by the overall market
Enanta (ENTA) is a biotech company focused on antiviral drugs. Its business is heavily dependent on royalties (for example, from AbbVie). When this chart shows rising fear, investors become nervous. They worry that during a recession, even large pharmaceutical partners could put pressure on royalties, making ENTA's R&D projects more difficult to finance.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Enanta Pharmaceuticals (ENTA)
Enanta is a biotech that receives huge royalties from AbbVie for its component in a Hepatitis C drug. Their future is betting on R&D (viruses, COVID-19). This chart measures how investors view this transition. It shows when the stock is overbought on the hype of new R&D or oversold on fears of falling royalties.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Enanta-Pharmaceuticals-ENTA&v=1772513737130 "RSI 14 indicator chart for the company's stock Enanta Pharmaceuticals (ENTA)")
RSI 14 Market Segment - Pharma virus
Enanta Pharmaceuticals is a biopharmaceutical company specializing in antiviral drugs. They are best known for their contributions to the development of hepatitis C treatments (in partnership with AbbVie). This chart reflects the overall sentiment in the biotech sector, helping to assess how the market views this speculative industry as a whole.
RSI 14 for the overall market
Enanta (ENTA) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ENTA (Enanta Pharmaceuticals)
Enanta (ENTA) is a biotech company focused on antiviral drug development, historically known for its contributions to hepatitis C treatment. This chart shows the average 12-month forecast. It reflects analysts' assessments of the potential of the company's new developments (e.g., against RSV).
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ENTA-Enanta-Pharmaceuticals&v=1772513737148 "A chart showing analyst consensus forecasts for the expected stock price. ENTA (Enanta Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price ENTA (Enanta Pharmaceuticals)
Enanta Pharmaceuticals is a biotech company specializing in antiviral drugs. Historically successful in hepatitis C, it is now focusing on RSV and COVID-19. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in the R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ENTA-Enanta-Pharmaceuticals&v=1772513737162 "A chart showing the difference between the consensus forecast and the actual stock price. ENTA (Enanta Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
Enanta Pharmaceuticals is a biotech company specializing in antiviral drugs. Historically successful in treating hepatitis C, it is now focusing on COVID-19 and RSV. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe the company's R&D pipeline will perform well in a post-pandemic world.
Analysts' consensus forecast for the overall market share price
Enanta Pharmaceuticals is a biopharmaceutical company specializing in antiviral drugs (hepatitis C, RSV). Their business model is R&D and royalties (they receive cash from AbbVie). This chart shows overall market sentiment. For Enanta, as an R&D company, it's important to understand how risk appetite (sentiment) influences the evaluation of their future developments. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biotech company specializing in antiviral drugs. Their success was built on royalties from AbbVie for their hepatitis C treatment. They are now using these funds for R&D in new areas (RSV, COVID-19). This chart evaluates their transition. It weighs their stable (but declining) royalties against the market's confidence in their new R&D pipeline.
AKIMA Market Segment Index - Pharma virus
Enanta Pharmaceuticals is a biotech company specializing in the development of drugs to treat viral infections, best known for its contributions to hepatitis C therapy. This chart shows the average index for the antiviral pharmaceutical sector. It helps investors assess how Enanta's performance, with its focus on R&D, compares to the industry average.
The AKIM Index for the overall market
Enanta Pharmaceuticals is a biotech company specializing in virology (hepatitis B, RSV, COVID-19). AbbVie's royalties are well-known. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this R&D company, which uses royalty revenue for new developments, compares to overall economic trends.
